Innovations in Cancer Genomics: Detection and Analysis of Genetic Alterations

by

Cancer genomics can be described as a relatively young yet rapidly progressing scientific discipline that focuses on the study of the genetic basis of cancer and the use of this knowledge to fight the disease. In addition, the following branch of science comprehensively examines the specific complicated genetic changes that characterize the development of various types of cancer. Over the years, there have been improvements in technology that have helped in the discovery and study of these alterations, hence making treatment more efficient and tailored. Advancements in genomic techniques like next-generation sequencing and advanced computational tools have opened the world of cancer genomics. Moreover, these advancements contribute not only to the identification of the genetic changes in cancer but also to the elucidation of their functional impacts, which would help in the identification of therapeutic targets.

Advancements in Genomic Technologies

Among those key innovations, the use of next-generation sequencing (NGS) is critical. It is another tool that implements the sequenced data of DNA and RNA to achieve high-throughput analysis and genetic differences with high resolution. This technology proved to be more advanced than the regular sequencing techniques since it gives a more encompassing view of the genome, exome, or transcriptome. is useful in teaching many genetic changes, such as point mutations, insertions, deletions, CNVs, and structural variations, to mention but a few, with reasonable accuracy and efficiency.

Copy Number Variation Detection

A CNV is a kind of genomic change that can be characterized by the increase or reduction in the size of certain sections of DNA. CNVs are involved in cancer development and its progression, and they increase tumor heterogeneity and resistance to therapy. These discoveries have been made easier together with the help of NGS and with the help of recently developed computational algorithms. For example, a new read-depth algorithm known as BIC-seq can in a precise and reliable way identify CNVs in WGS data. This algorithm also slashes the Bayesian information criterion to look for CNVs with high sensitivity and true positive rates and CNVs as small as 40 bps. Theoretically, these specific detection features are valuable for studying the genomic features of cancer and designing molecular therapies.

Yearwise Publication Trend on “cancer genomics”

Find publication trends on relevant topics

Mutual Exclusivity Analysis

In cancer genomes, various genetic changes are observed to occur that are mainly routes for specific pathways. Most of the oncogenic network modules have been revealed by applying the mutual exclusivity analysis to the patterns of genetic changes. The MEMo (Mutual Exclusivity Modules in Cancer) algorithm utilizes Pearson’s r and permutation tests to unveil network modules with multiple alterations that are mutually exclusive. This approach has been done for data of TCGA, and important altered modules have been found in glioblastoma and serous ovarian cancer. It contributes to defining selective conditions promoting tumorigenesis and can be valuable in designing the appropriate pairs of agents that would give a synergistic lethal effect.

Integrative Genomics and Functional Analysis

DNA copy number, gene expression, and epigenetic modifications are the various facets of cancer genomics, and their combined analysis offers comprehensive data. This integrative approach is necessary for the identification of the multifaceted characteristics of cancer and its progression.

Genomic and Epigenetic Profiling

Integrative genomics incorporates the information obtained from the various omics platforms to decipher the genetic and epigenetic changes that cause cancer. For example, spectral karyotyping, aCGH, and global gene expression have been employed jointly to investigate PCM and established carcinoma cell lines. These findings indicate that the majority of chromosome breakpoints occur at the sites of CNVs and demonstrate that genes residing in high-level copy number changes are significantly dysregulated across samples. The knowledge of these genomic and epigenetic changes is crucial for the molecular mechanism understanding of transcriptional dysregulation in cancer and can point to the possible therapeutic intervention points.

Patient-Specific Pathway Activities

Mass-throughput platforms can assess multiple aspects of genomic copy number status, gene expression, DNA methylation, and epigenetic states within a single cancer sample at the same time. A new approach known as PARADIGM (Pathway Recognition Algorithm using Data Integration on Genomic Models) has been created to predict what genetic activities occur in a specific patient based on interactions among genes in curated pathways. Compared to other methods described above, this method utilizes probabilistic inference of the extent of activities of pathways in patients to derive a more accurate quantitative measure of the molecular pathogenesis of cancer. Lumping of patients based on major pathway alterations may classify them into distinctive prognosis groups for which significant variations in remedy are possible.

Recent Publications on “cancer genomics”

Find publications on relevant topics

Specific Genetic Alterations and Their Implications

Somatic Mutations in Chromatin Remodeling Genes

Non-coding genes, some of which are chromatin remodeling genes like ARID1A, are involved in controlling the stringency of DNA for transcription. Thus, based on the present literature, ARID1A gene mutations have been reported in different tumors, such as ovarian clear cell carcinomas, gastrointestinal cancers, etc. These mutations also bring about improper formation of chromatin and hence are involved in tumorigenesis. Keywords: ARID1A, mutation, cancer, target Signed up for targeted therapies that address the effects of these genetic changes may be beneficial for understanding the parts and period of the disease.

Oncogenic Transcription Factors

Some proteins have also been determined to cause the disease, and they are called the oncogenes, for example, nuclear factor I/B (Nfib) in small cell lung cancer (SCLC). These transcription factors control cell survival and growth during transformation and, so, may be factors for possible drugs. Learning from the studies concerning oncogenic transcription factors’ amplification and functional roles, scientists possess the knowledge to block these proteins’ functions and cancer development consequently.

Voltage-Gated Sodium Channels and Cancer Invasion

Among these, voltage-gated sodium channels (VGS), especially the SCN5A gene that encodes the Na(v)1.5 channels, have been reported to be involved in the metastatic ability of cancer cells. In colon cancer, VGSC activity is related to invasiveness and clinical significance has been confirmed by immunohistochemical staining of tissue samples derived from the patients. Thus, knowledge of the mechanisms concerning VGSC participation in cancer invasion can form a basis for creating pharmacological inhibitors capable of decreasing the metastatic capacity as well as enhancing patients’ prognosis.

Practical Applications and Future Directions

The changes in genomics significantly impact the diagnosing, estimating prognosis, and perhaps most importantly, the attempts to create precise treatment methods. Using these innovations, they can establish unique sequences of treatment necessary for genes that are altered in the tumors of certain patients.

Personalized Medicine

The determination of the genetic changes as well as the levels of pathway activity unique to a patient advance the creation of targeted therapeutic strategies. For example, treatments can be made to focus on the individual mutation or over/underactivity of certain pathways, thus increasing the potency of the treatment and reducing side effects. Personalized medicine paves the way for increasing the life span and improving the quality of life of cancer patients.

Novel Therapeutic Targets

This approach of sequencing entire cancer genomes identifies new targets that can be used for designing drugs for the treatment of cancer. For instance, the recognition of the dual cooperation and competition between oncogenic modules could point to the possibility of synthetic lethality. Combination therapies can improve the efficiency of treatment and diminish the effects of the factors mentioned above if these modules are targeted.

Epigenetic Modifications

The concept of what epigenetic changes like DNA methylation and histone modification are and the part they play in the progression of cancer allows for therapeutic interference. Some of the epigenetic therapies include DNA methyltransferase inhibitors and histone deacetylase inhibitors, which help change the abnormal pattern of gene expression and get the cells back to normal function.

Conclusion

Advancements in the field of cancer genomics have given a new dimension to the genomic changes that are the root cause of cancer. Apart from the individual research projects, new post-genomic techniques and methodologies, system biology approaches, and, finally, functional studies have revealed the multifaceted view of the cancer genomes and potential therapeutic targets. This means that diagnostic assessments also help in the detection of gene changes, which facilitates the design of therapeutic plans in the field of oncology. Therefore, it can be assumed that new approaches to diagnostics and treatment will remain unlocked in the future for better and more precise cancer therapies.

References

  1. Bogaert J, Prenen H. Molecular genetics of colorectal cancer. Ann Gastroenterol. 2014;27(1):9-14. PMID: 24714764; PMCID: PMC3959535.
  2. Ciriello G, Cerami E, Sander C, Schultz N. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res. 2012 Feb;22(2):398-406. doi: 10.1101/gr.125567.111. Epub 2011 Sep 9. PMID: 21908773; PMCID: PMC3266046.
  3. Xi R, Hadjipanayis AG, Luquette LJ, Kim TM, Lee E, Zhang J, Johnson MD, Muzny DM, Wheeler DA, Gibbs RA, Kucherlapati R, Park PJ. Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion. Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):E1128-36. doi: 10.1073/pnas.1110574108. Epub 2011 Nov 7. PMID: 22065754; PMCID: PMC3219132.
  4. Jones S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, Schmidt MK, Markowitz S, Yan H, Bigner D, Hruban RH, Eshleman JR, Iacobuzio-Donahue CA, Goggins M, Maitra A, Malek SN, Powell S, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat. 2012 Jan;33(1):100-3. doi: 10.1002/humu.21633. Epub 2011 Nov 23. PMID: 22009941; PMCID: PMC3240719.
  5. House CD, Vaske CJ, Schwartz AM, Obias V, Frank B, Luu T, Sarvazyan N, Irby R, Strausberg RL, Hales TG, Stuart JM, Lee NH. Voltage-gated Na+ channel SCN5A is a key regulator of a gene transcriptional network that controls colon cancer invasion. Cancer Res. 2010 Sep 1;70(17):6957-67. doi: 10.1158/0008-5472.CAN-10-1169. Epub 2010 Jul 22. PMID: 20651255; PMCID: PMC2936697.
  6. Camps J, Nguyen QT, Padilla-Nash HM, Knutsen T, McNeil NE, Wangsa D, Hummon AB, Grade M, Ried T, Difilippantonio MJ. Integrative genomics reveals mechanisms of copy number alterations responsible for transcriptional deregulation in colorectal cancer. Genes Chromosomes Cancer. 2009 Nov;48(11):1002-17. doi: 10.1002/gcc.20699. PMID: 19691111; PMCID: PMC4721599.
  7. Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, Haussler D, Stuart JM. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics. 2010 Jun 15;26(12):i237-45. doi: 10.1093/bioinformatics/btq182. PMID: 20529912; PMCID: PMC2881367.
  8. Ewan K, Pajak B, Stubbs M, Todd H, Barbeau O, Quevedo C, Botfield H, Young R, Ruddle R, Samuel L, Battersby A, Raynaud F, Allen N, Wilson S, Latinkic B, Workman P, McDonald E, Blagg J, Aherne W, Dale T. A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription. Cancer Res. 2010 Jul 15;70(14):5963-73. doi: 10.1158/0008-5472.CAN-10-1028. Epub 2010 Jul 7. PMID: 20610623; PMCID: PMC2912498.
  9. Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, Boutselakis H, Cole CG, Creatore C, Dawson E, Fish P, Harsha B, Hathaway C, Jupe SC, Kok CY, Noble K, Ponting L, Ramshaw CC, Rye CE, Speedy HE, Stefancsik R, Thompson SL, Wang S, Ward S, Campbell PJ, Forbes SA. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947. doi: 10.1093/nar/gky1015. PMID: 30371878; PMCID: PMC6323903.
  10. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, Perner S, Prensner J, Debiasi RM, Demichelis F, Hatton C, Rubin MA, Garraway LA, Nelson SF, Liau L, Mischel PS, Cloughesy TF, Meyerson M, Golub TA, Lander ES, Mellinghoff IK, Sellers WR. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12. doi: 10.1073/pnas.0710052104. Epub 2007 Dec 6. PMID: 18077431; PMCID: PMC2148413.

Top Experts on “cancer genomics“